The interpretation of the results of the use of vigabatrin (VGB) in generalized seizures and epilepsies in children has been difficult. Most studies have assessed patients on the basis of both seizure type and epilepsy syndrome and the numbers of patients have been small. Some 'generalized' epilepsy syndromes {specifically the Lennox-Gastaut syndromel are characterized by multiple seizure types which are frequently not analysed individually in terms of drug response. By contrast West syndrome is easier to evaluate as the spasms are the only, and characteristic, seizure type. Vigabatrin has been used as both add-on, and mohotherapy in the treatment of spasms. The results of add-on studies suggest that symptomatic spasms respond best, with 40-100% of chilren becoming spasm-free and many others showing a reduction in seizures of over 50%. The limited, reported data on VGB-monotherapy in West syndrome have been encouraging with over 50% of patients experiencing a total and sustained control of seizures with minimal or no adverse events; however, the pattern of response (symptomatic cases responding better than cryptogenic casesl, has not, as yet, been confirmed. The 'non-progresive' myoclonic epilepsies tend to be exacerbated with 25-50% of patients experiencing an increase in seizure frequency; this is an interesting observation in view of the improvement seen in infantile spasms, which are also classified as a myoclonic seizure. The use of VGB in other generalized seizures and epilepsy syndromes has been neither assessed, nor reported. This reflects the fact that these seizures/ syndromes are easily and well controlled using the 'older' anti-epileptic drugs.
INTRODUCTION
The introduction (and licensing) of vigabatrin in 1989 was for the treatment of epilepsy which was not satisfactorily controlled by other anti-epileptic drugs; to date, its predominant prescription has been in refractory partial (cryptogenic/symptomatic localization-related' seizures and epilepsies, in which it has achieved considerable success 2"3. Its use has subsequently been extended to generalized symptomatic/crypt0genic seizures (and epilepsy syndromes) in which both the reporting of results, and success, has been more limited. The purpose of this paper is to review the efficacy of vigabatrin in generalized seizures and epilepsies principally in the West and LennoxGastaut syndromes.
WEST SYNDROME
Until recently the treatment of spasms in West syndrome relied upon anecdotal and retrospec-1059-1311/95/010045+04 $08.00/0 tive studies, using drugs which have an unknown mechanism and serious side effects. Vigabatrin is the first of the 'newer' antiepileptic drugs to be used in this syndrome, initially as 'add-on '4, and subsequently as monotherapy 5.6.
In a single, uncontrolled study VGB was effective in controlling previously drug-resistant spasms; this open, add-on study involved 70 children, aged between 2 months and 13 years in whom the onset of spasms was under the age of 1 year 4. The spasms were classified as symptomatic (33 patients) and cryptogenic (37 patients); aetiologies in the symptomatic cases included tuberous sclerosis (14), other cerebral malformations (9) and ischaemia (6) . The dosage of VGB was 50-150 mg/kg/day in children and 100-200mg/kg/day in infants; 66 children were receiving other anti-epileptic drugs at the time VGB was introduced. The patients were assessed at 5 months (evaluation phase) and subsequently for up to 33 months (long-term phase). Thirty-seven of the 68 patients (54%) who were evaluated at 5 months showed resolution of spasms; efficacy was particularly striking in patients with symptomatic spasms due to tuberous sclerosis with 10 of 14 (71%) showing a complete suppression (Fig.  1) . In the long-term phase, in which 55 patients were evaluated, 30 (55%) continued to show a complete resolution of spasms including all the patients with tuberous sclerosis (Fig. 1) . In the patients who experienced complete control of their spasms, eight were ultimately controlled on VGB-monotherapy. An additional 10% of patients showed a 50% or greater reduction in spasms. The data showed clearly that patients with symptomatic spasms responded better than those with cryptogenic spasms, which is contrary to current textbook teaching. Adverse events were common, occurring in 26% of patients; sedation, hypotonia and agitation were the most frequently encountered, and two patients required early withdrawal of VGB, due to hypertonia and hypotonia, respectively. Finally, tolerance (leading to discontinuation of the drug) developed in 10 of the 55 patients (18%). In view of this preliminary data, suggesting that VGB may be an effective and safe drug in the treatment of spasms, attention has, not surprisingly, focused on using it as the initial preferred drug 5'6, instead of ACTH and corticosteroids.
At the Royal Liverpool Children's Hospital, Alder Hey, VGB has been used as initial monotherapy in the treatment of infantile spasms for the past 2 years: the first 15 children have already been reported 5. To date 20 children, aged 3-11 months, have been treated, 14 with symptomatic, four with cryptogenic and two with idiopathic (normal development and neurological findings), spasms. Aetiologies in the symptomatic cases included cerebral dysgenesis (seven patients), neonatal hypoxic ischaemic encephalopathy (2), perinatal periventricular haemorrhage (2), tuberous sclerosis (2) and unilateral cerebral astrocytoma (1). Vigabatrin was started at diagnosis at 50-80 mg/kg/day increasing over 3 days to a maximum of 100-150 mg/kg daily. Overall, 16 of the 20 patients (80%) showed 75% or greater reduction in spasms; 13 of these 16 patients (65% of the entire group) showed a complete suppression of spasms which has been sustained for up to 30 months. The results are summarized in Table 1 . Only four of the 20 patients demonstrated no response to VGB; alternative treatments in these patients (including ACTH, sodium valproate and nitrazepam) have not completely suppressed the spasms. The most striking observation was that all those children who responded did so within 72 hours of starting treatment, including total suppression. Hypsarrhythmia disappeared in all seven patients who showed a sustained resolution of the spasms including the two children with idiopathic, three of the four children with cryptogenic, and two of the 14 children with symptomatic spasms (due to tuberous sclerosis and cerebral dysgenesis, respectively). In those patients who suffered a relapse of spasms after initial control there was no clear pattern of response in terms of the EEG; in some patients the hypsarrhythmia persisted during control and relapse, while in others the EEG remained abnormal but not obviously hypsarrhythmic.
There were no aetiological, clinical or electroencephalographic features (data not shown) which distinguished responders from nonresponders, but this probably reflects the small number of patients in the study; the two chil-dren with 'idiopathic' spasms have shown a complete, and sustained control, with no other seizure types and normal development, as have three of the four children with cryptogenic spasms.
There did not appear to be an obvious doseresponse relationship, although this was not formally assessed; it was our impression that most of the responders showed a dramatic reduction in spasms at the lower, introductory dose of 50-80 mg/kg/day. No dose response has been demonstrated in a formal, dose-ranging study undertaken in older children 7.
No adverse side-effects were seen in the 20 patients.
A more recent report from the Netherlands 6 describes six children aged between 3 and 6 months, treated with VGB monotherapy. Three had symptomatic, and three cryptogenic spasms. The dose of VGB was 50mg/kg/day initially increasing, if necessary, to 100 mg/kg/ day. All six children showed a 50% or greater reduction in spasms. In two the response was complete (100%) and sustained for up to 24 months; in two others there was a relapse after initial complete control (relapse of spasms in one, development of other seizure types in the other) and the remaining two showed a reduction of 50% and 90% of spasms (both demonstrated improved control at the higher dose). There was no comment on the rate of response, i.e. how rapidly spasms ceased after the drug was started. Adverse events occurred in two children (hypotonia, hyperactivity).
The only other published report (abstract form only), describes five patients who were reported to show a 50-75% reduction in spasms after 6 months of treatment--no further details were available s.
These preliminary data suggest that vigabatrin could be considered as the preferred, initial treatment for infantile spasms. The response rate indicates that if spasms have not been controlled after 5 or 6 days of treatment with VGB, alternative anti-epileptic drugs can then be introduced without affecting the shortterm or long-term outcome, with respect to control of spasms, the development of'late' epilepsy or intellectual function. However, there are still some outstanding questions regarding the use of VGB, particularly the long-term effects of the drug, and how long after control of the spasms the drug can be withdrawn; with regard to this latter question we have recently and successfully withdrawn VGB after 12, 16 and 24 months of complete seizure control in three children. It is likely that the drug could be discontinued after a shorter period of treatment, but this needs further evaluation and confirmation.
LENNOX-GASTAUT SYNDROME
The Lennox-Gastaut syndrome is considered by many to be an extension of West syndrome and is characterized by multiple seizure types; unfortunately the syndrome or label is frequently over-diagnosed and is often used inappropriately for any patient with difficult epilepsy. As a result, evaluation of patients with the syndrome has been difficult.
Published data reporting the use of VGB in children with Lennox-Gastaut syndrome are limited and the results are inconsistent. An open add-on study (published in abstract form only) 9 of 20 patients, reported that 60% of patients experienced a 60-100% reduction in seizures, although it was unclear whether just one, or all, seizure types were reduced. In other studies 2'1°, a seizure reduction of between 30 and 50% in Lennox-Gastaut syndrome has been reported in 40-50% of patients but the numbers involved have been very small (often less than 10), and again, analysis has not usually been performed on specific seizure types. In our series of 43 patients, six of whom had the Lennox-Gastaut syndrome, none of them achieved a greater than 25% reduction in total seizure frequency 3.
NON-PROGRESSIVE MYOCLONIC SEIZURES
Most studies have demonstrated that myoclonic seizures, occurring either in isolation, or in one of the non-progressive myoclonic epilepsies, tend to be exacerbated 2'3 occasionally necessitating withdrawal of VGB. In our experience this has occasionally been accompanied by an increase in spike or polyspike activity in the EEG in a number of patients. This is an interesting observation in view of the beneficial effect of VGB on infantile spasms, which are also classified as a myoclonic seizure; these observations are not necessarily contradictory and may be explained by the heterogenous pathophysiology of infantile spasms. Thus, for instance, symptomatic cases with focal pathology (e.g. unilateral dysgenesis or tumour) may cause partial seizures with rapid secondary general-ization, manifest as clusters of spasms; this has been confirmed by simultaneous split-screen video-EEG recording, in both our, and others' experience. (This may have implications for any future classifications of epilepsies and epilepsy syndromes.) That partial, secondarily generalized seizures (in this case spasms) should respond well to VGB is not surprising given the proven efficacy of the drug in partial (particularly symptomatic) seizures 2"3' ~o.
OTHER GENERALIZED EPILEPSIES--IDIOPATHIC
The use of VGB in the idiopathic generalized epilepsies (group 2.1 in the 1989 ILAE Classification l) has either not been evaluated or has not been reported. This is not unexpected as the majority of these epilepsies (and seizures) tend to be relatively well-controlled with the 'older' anti-epileptic drugs, and have a generally benign outcome. The numbers of patients experiencing 'primary' generalized tonicclonic, tonic or absence seizures and treated with VGB have been small and less than 30c~ of patients have experienced at least a 50c~ reduction in seizures 2'3. Finally, our own observations would suggest that the early morning myoclonic seizures seen in juvenile myoclonic epilepsy may occur more frequently in patients treated with this drug.
CONCLUSION
Vigabatrin has been used infrequently, and with limited success in the generalized epilepsies and epilepsy syndromes of childhood. The one 'generalized' epilepsy syndrome where the drug appears to be both effective and safe, and offer a clear advantage compared to the older, more established treatments, is West syndrome, particularly if of symptomatic origin. Information on both the duration of treatment R.E. Appleton with VGB in this syndrome, and on the longterm effects of the drug is still required; in the interim VGB should arguably become the preferred, initial drug for the treatment of infantile spasms and West syndrome.
